Fig. 4: CDNP-R848 treatment effect is independent of CD8 and CD4 T cells, and NK cells.

a–c Waterfall plot of tumor volumes (left) and response assessment (right) for immune cell depletion experiments. CD8⁺ T cells, CD4⁺ T cells or NK1.1⁺ were depleted prior to and during CDNP-R848 therapy using monoclonal depletion antibodies. Tumor volume (% between d13 and d26) and response assessment of CD8⁺ T cell-depleted or isotype treated mice (CDNP-R848 + CD8 isotype n = 5 vs CDNP-R848 + α-CD8 depleted, n = 6 animals, a), CD4⁺ T cell-depleted or isotype treated mice (CDNP-R848 + CD4 isotype n = 6 vs CDNP-R848 + α-CD4 depleted, n = 5 mice, b) and NK1.1+ depleted or isotype treated mice (CDNP-R848 + NK1.1 isotype, n = 7 vs CDNP-R848 + α-NK1.1 depleted, n = 7 animals, c). d Tumor growth of the different treatment and depletion groups (α-NK1.1 depleted, n = 7 animals; α-CD8 depleted, n = 6 animals, α-CD4 depleted, n = 5 mice; CDNP-R848 + isotype n = 18 mice; CDNP + isotype, n = 4 mice). The data are from one independent experiment and presented as mean ± SEM. Statistical significance was determined by two-tailed Student’s t test.